Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Mar 16;4(6):879–889. doi: 10.1158/1940-6207.CAPR-11-0025

Table 1.

P53 mutations and drug-resistance in neuroblastoma cell lines

Status of p53 Cell line p53
Mutation
IC50 (μM)
DOX CDDP
Mutated CHLA90 E286K 0.60 ± 0.1 30 ± 4
SK-N-BE(2) C135F 0.88 ± 0.1 22 ± 2
Wild-type SMS-KCNR 0.02 ± 0.0 4 ± 1
LA –N-5 0.02 ± 0.0 10 ± 1

Drug-sensitivity assays were performed using MTT to determine IC50 values. The values are presented as mean ± SD from three separate determinations with eight replicates each (n = 24)